Extract from the above information

Propylthiouracil is a thiourea antithyroid drug that mainly inhibits the synthesis of thyroxine. Its mechanism of action is to inhibit the oxidation of iodide taken into the thyroid gland and the coupling of tyrosine by inhibiting thyroid endoperoxidase, thereby hindering the synthesis of thyroid hormone (T4) and triiodothyronine. In addition, propylthiouracil also inhibits the deiodination of T4 in peripheral tissues to produce T3.

It is a commonly used purine metabolism antagonist drug that inhibits the purine synthesis pathway. It is a cell cycle-specific drug that is most sensitive to cells in the S phase. In addition to inhibiting the synthesis of cell DNA, it also has a mild inhibitory effect on the synthesis of RNA. This product is an analog of guanine. It must be converted into 6-TG ribonucleotides by phosphoribosyltransferase in the human body to be active. The action link of this product is similar to that of mercaptopurine. In addition, 6-TG ribonucleotides can prevent the phosphorylation of guanosine monophosphate (GMP) to guanosine diphosphate (GPD) by inhibiting guanylate kinase. After being metabolized to deoxyribose triphosphate, this product can be incorporated into DNA, thereby further inhibiting the biosynthesis of nucleic acids. Mercaptopurine does not have this effect. This product has effective cross-resistance with mercaptopurine, and can improve the efficacy when used in combination with drugs such as cytarabine.

This product is a medium-acting anticoagulant of the dicoumarin class. Its mechanism of action is to competitively counteract the effect of vitamin K, inhibit the synthesis of coagulation factors in hepatocytes, and also has the effect of reducing thrombin-induced platelet aggregation reaction, thus having anticoagulant and antiplatelet aggregation functions.